TANG KEVIN C's Q4 2020 13F: 1 position resized, no new positions or exits
Form 13F-HR for the quarter ended Dec 31, 2020 · filed Feb 16, 2021 · 2 reported positions · accession 0001214659-21-001969
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Reduced | HERON THERAPEUTICS INC (HRTX) | 21.8% | 7.3% | −14.5 pts | −14,713 sh | −81% |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 100.0% of the equity book
No changes in the top 10 this quarter
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | LA JOLLA PHARMACEUTICAL CO (LJPC) | 78.2% | 92.7% | |
| 2 | HERON THERAPEUTICS INC (HRTX) | 21.8% | 7.3% |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).